Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Ligand Pharmaceuticals announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the…
Read More...
Read More...